Metrika

  • citati u SCIndeksu: 0
  • citati u CrossRef-u:0
  • citati u Google Scholaru:[]
  • posete u poslednjih 30 dana:2
  • preuzimanja u poslednjih 30 dana:0

Sadržaj

članak: 4 od 161  
Back povratak na rezultate
Troškovi lečenja teškog pogoršanja HOBP-a u Srbiji
aUniverzitet u Kragujevcu, Fakultet medicinskih nauka
bPharmaceutical Chamber of Serbia, Belgrade
cPharmaceutical Chamber of Federation of Bosnia and Herzegovina, Sarajevo, Bosnia and Herzegovina

e-adresarpavlovic@medf.kg.ac.rs
Ključne reči: HOBP; teško pogoršanje; hospitalizacija; troškovi
Sažetak
Glavni cilj ovog istraživanja je bio da se utvrdi i prikaže ekonomski aspekt ozbiljnih pogoršanja HOBP-a koje zahtevaju hospitalizaciju i razlike u troškovima lečenja između grupe pacijenata čestih egzacerbatora - sa najmanje dva pogoršanja tokom jedne godine i grupe pacijenata sa jednim pogoršanjem. Naši rezultati sugerišu da značajno više resursa treba potrošiti za lečenje pacijenata sa najmanje dve hospitalizacije tokom jedne godine i to za upotrebu lekova koji prvenstveno utiču na respiratorni sistem (kortikosteroidi, p = 0.013, teofilin, p = 0.007 ), ukupan boravak u bolnici (31336.68 ± 19140 dinara u odnosu na 23650.15 ± 14956.0 dinara, ili izraženo u eurima 517.53 ± 316.1 EUR/ 390.59 ± 247 EUR, p = 0.002), boravak u poluintenzivnoj jedinici, 12875.35 ± 20742.54 dinara naspram 4310.62 ± 9779.78 dinara, odnosno 212.64 ± 342.57 EUR /71.19 ± 161.51 EUR (p = 0.006). Posmatrajući ukupan broj dana u bolnici, novac za lekove, korišćeni materijal i pružene usluge, značajno više sredstava je utrošeno za lečenje pacijenata iz grupe čestih egzacerbatora, 80034.1 ± 36823.7 RSD / 1321, 78 ± 608.15EUR, naspram 69425.5 ± 34083.1 RSD / 1146.58 ± 562.89 EUR za grupu pacijenata sa jednom egzacerbacijom (p = 0.039). Može se zakljućiti da će značajno više sredstava biti potrošeno u lečenju pogoršanja pacijenata koji pripadaju grupi čestih egzacerbatora. Ovi pacijenti će boraviti duže u bolnici ili u jedinici poluintenzivne nege, upotrebiće se značajno više lekova koji se prvenstveno koriste u lečenju respiratornog sistema, a samim tim će i troškovi biti značajno veći.
Reference
Abudagga, A., Sun, S.X., Tan, H., Solem, C.T. (2013) Exacerbations among chronic bronchitis patients treated with maintenance medications from a US managed care population: An administrative claims data analysis. International Journal of Chronic Obstructive Pulmonary Disease, 8, 175-185
Blasi, F., Cesana, G., Conti, S., Chiodini, V., Aliberti, S., Fornari, C., Mantovani, L.G. (2014) The clinical and economic impact of exacerbations of chronic obstructive pulmonary disease: A cohort of hospitalized patients. PLoS ONE, 9(6), 1-8
Cazzola, M., Bettoncelli, G., Sessa, E., Cricelli, C., Biscione, G. (2010) Prevalence of comorbidities in patients with chronic obstructive pulmonary disease. Respiration, 80(2), 112-119
Diamantea, F., Kostikas, K., Bartziokas, K., Karakontaki, F., Tsikrika, S., Pouriki, S., Polychronopoulos, V., Karagiannidis, N., Haniotou, A., Papaioannou, A.I. (2014) Prediction of hospitalization stay in COPD Exacerbations: The AECOPD-F score. Respiratory Care, 59(11), 1679-1686
Doos, L., Uttley, J., Onyia, I., Iqbal, Z., Jones, P.W., Kadam, U.T. (2014) Mosaic segmentation, COPD and CHF multimorbidity and hospital admission costs: A clinical linkage study. J Public Health (Oxf ), 36(2), 317-324
Global Initiative for Chronic Obstructive Lung Disease (2014) Global strategy for the diagnosis: Management and prevention of chronic obstructive pulmonary disease. http://www.goldcopd.org
Guarascio, A.J., Ray, S.M., Finch, C.K., Self, T.H. (2013) The clinical and economic burden of chronic obstructive pulmonary disease in the USA. Clinicoecon Outcomes Res, 5, 235-245
Halpin, D.M., Miravitlles, M. (2006) Chronic obstructive pulmonary disease: The disease and its burden to society. Proceedings of the American Thoracic Society, 3(7), 619-623
Harries, T.H., Thornton, H.V., Crichton, S., Schofield, P., Gilkes, A., White, P.T. (2015) Length of stay of COPD hospital admissions between 2006 and 2010: A retrospective longitudinal study. International Journal of Chronic Obstructive Pulmonary Disease, 10, 603-611
Hertel, N., Kotchie, R.W., Samyshkin, Y., Radford, M., Humphreys, S., Jameson, K. (2012) Cost-effectiveness of available treatment options for patients suffering from severe COPD in the UK: A fully incremental analysis. International Journal of Chronic Obstructive Pulmonary Disease, 7, 183-199
Hillas, G., Perlikos, F., Tsiligianni, I., Tzanakis, N. (2015) Managing comorbidities in COPD. Int J Chron Obstruct Pulmon Dis, 10, 95-109
Hoogendoorn, M., Kappelhoffb, S., Overbeek, J.A., Wouters, E.F., Rutten-Van, M.M.P. (2012) Which long-acting bronchodilator is most cost-effective for the treatment of COPD?. Neth J Med. Review, 70(8), 357-364
Hurst, J.R., Vestbo, J., Anzueto, A., Locantore, N., Müllerova, H., Tal-Singer, R., Miller, B., Lomas, D.A., Agusti, A., Macnee, W., Calverley, P., Rennard, S., Wouters, E.F.M., Wedzicha, J.A. (2010) Susceptibility to exacerbation in chronic obstructive pulmonary disease. New England Journal of Medicine, 363(12), 1128-1138
Lazić, Z., Gajović, O., Tanasković, I., Milovanović, D., Atanasijević, D., Jakovljević, M. (2012) GOLD stage impact on COPD direct medical costs in the elderly. Health Behav & Pub Health, 2(3), 1-7
Lozano, R., Naghavi, M., Foreman, K., Lim, S., Shibuya, K., Aboyans, V., et al. (2012) Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: A systematic analysis for the Global Burden of Disease Study 2010. Lancet, 380(9859), 2095-2128
Mannino, D.M., Watt, G., Hole, D., Gillis, C., Hart, C., McConnachie, A., Smith, D.G., Upton, M., Hawthorne, V., Sin, D.D., Man, S.F., van Eeden, S., Mapel, D.W., Vestbo, J. (2006) The natural history of chronic obstructive pulmonary disease. European Respiratory Journal, 27(3), 627-643
Mapel, D.W., Hurley, J.S., Frost, F.J., Petersen, H.V., Picchi, M.A., Coultas, D.B. (2000) Health care utilization in chronic obstructive pulmonary disease. A casecontrol study in a health maintenance organization. Arch Intern Med, 160(17), 2653-2658
Mathers, C.D., Loncar, D. (2006) Projections of global mortality and burden of disease from 2002 to 2030. PLoS Medicine, 3(11), 2011-2030
Menn, P., Leidl, R., Holle, R. (2012) A lifetime Markov model for the economic evaluation of chronic obstructive pulmonary disease. PharmacoEconomics, 30(9), 825-840
Montserrat-Capdevila, J., Godoy, P., Marsal, J.R., Barbé, F., Galván, L. (2015) Risk of exacerbation in chronic obstructive pulmonary disease: A primary care retrospective cohort study. BMC Family Practice, 16(1), 173
Örnek, T., Tor, M., Altın, R., Atalay, F., Geredeli, E., Soylu, Ö., Erboy, F. (2012) Clinical factors affecting the direct cost of patients hospitalized with acute exacerbation of chronic obstructive pulmonary disease. International Journal of Medical Sciences, 9(4), 285-290
Parikh, R., Shah, T., Tandon, R. (2016) COPD exacerbation care bundle improves standard of care, length of stay, and readmission rates. International Journal of Chronic Obstructive Pulmonary Disease, 11(1), 577-583
Pasquale, M.K., Sun, S.X., Song, F., Hartnett, H.J., Stemkowski, S.A. (2012) Impact of exacerbations on health care cost and resource utilization in chronic obstructive pulmonary disease patients with chronic bronchitis from a predominantly Medicare population. International Journal of Chronic Obstructive Pulmonary Disease, 7, 757-764
Säynäjäkangas, O., Kinnunen, T., Tuuponen, T., Keistinen, T. (2004) Length of stay and interval to readmission in emergency hospital treatment of COPD. Age Ageing, 33(6), 567-570
Valente, S., Pasciuto, G., Bernabei, R., Corbo, G.M. (2010) Do we need different treatments for very elderly COPD patients?. Respiration, 80(5), 357-368
Wan, E.S., Demeo, D.L., Hersh, C.P., Shapiro, S.D., Rosiello, R.A., Sama, S.R., Fuhlbrigge, A.L., Foreman, M.G., Silverman, E.K. (2011) Clinical predictors of frequent exacerbations in subjects with severe chronic obstructive pulmonary disease (COPD). Respiratory Medicine, 105(4), 588-594
World Health Organisation (2011) Chronic obstructive pulmonary disease (COPD). http://www.who.int/respiratory/copd/en
Yu, A.P., Yang, H., Wu, E.Q., Setyawan, J., Mocarski, M., Blum, S. (2011) Incremental third-party costs associated with COPD exacerbations: A retrospective claims analysis. Journal of Medical Economics, 14(3), 315-323
 

O članku

jezik rada: engleski
vrsta rada: izvorni naučni članak
DOI: 10.2478/SJECR-2018-0010
objavljen u SCIndeksu: 02.07.2020.